» Articles » PMID: 28535182

Characterization of Liver Injury, Oval Cell Proliferation and Cholangiocarcinogenesis in Glutathione S-transferase A3 Knockout Mice

Overview
Journal Carcinogenesis
Specialty Oncology
Date 2017 May 24
PMID 28535182
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

We recently generated glutathione S-transferase (GST) A3 knockout (KO) mice as a novel model to study the risk factors for liver cancer. GSTA3 KO mice are sensitive to the acute cytotoxic and genotoxic effects of aflatoxin B1 (AFB1), confirming the crucial role of GSTA3 in resistance to AFB1. We now report histopathological changes, tumor formation, biochemical changes and gender response following AFB1 treatment as well as the contribution of oxidative stress. Using a protocol of weekly 0.5 mg AFB1/kg administration, we observed extensive oval (liver stem) cell (OC) proliferation within 1-3 weeks followed by microvesicular lipidosis, megahepatocytes, nuclear inclusions, cholangiomas and small nodules. Male and female GSTA3 KO mice treated with 12 and 24 weekly AFB1 injections followed by a rest period of 12 and 6 months, respectively, all had grossly distorted livers with macro- and microscopic cysts, hepatocellular nodules, cholangiomas and cholangiocarcinomas and OC proliferation. We postulate that the prolonged AFB1 treatment leads to inhibition of hepatocyte proliferation, which is compensated by OC proliferation and eventually formation of cholangiocarcinoma (CCA). At low-dose AFB1, male KO mice showed less extensive acute liver injury, OC proliferation and AFB1-DNA adducts than female KO mice. There were no significant compensatory changes in KO mice GST subunits, GST enzymatic activity, epoxide hydrolase, or CYP1A2 and CYP3A11 levels. Finally, there was a modest increase in F2-isoprostane and isofuran in KO mice that confirmed putative GSTA3 hydroperoxidase activity in vivo for the first time.

Citing Articles

Species Differences in the Biotransformation of Aflatoxin B1: Primary Determinants of Relative Carcinogenic Potency in Different Animal Species.

Eaton D, Williams D, Coulombe R Toxins (Basel). 2025; 17(1).

PMID: 39852983 PMC: 11768628. DOI: 10.3390/toxins17010030.


Early Deregulation of Cholangiocyte NR0B2 During Primary Sclerosing Cholangitis.

Desterke C, Chung C, Pan D, Trauner M, Samuel D, Azoulay D Gastro Hep Adv. 2024; 2(1):49-62.

PMID: 39130146 PMC: 11307415. DOI: 10.1016/j.gastha.2022.07.023.


Molecular Signatures Integral to Natural Reprogramming in the Pigment Epithelium Cells after Retinal Detachment in .

Markitantova Y, Fokin A, Boguslavsky D, Simirskii V, Kulikov A Int J Mol Sci. 2023; 24(23).

PMID: 38069262 PMC: 10707686. DOI: 10.3390/ijms242316940.


Gender Differences in Oxidative Stress in Relation to Cancer Susceptibility and Survival.

Allegra A, Caserta S, Genovese S, Pioggia G, Gangemi S Antioxidants (Basel). 2023; 12(6).

PMID: 37371985 PMC: 10295142. DOI: 10.3390/antiox12061255.


Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance.

Calvisi D, Boulter L, Vaquero J, Saborowski A, Fabris L, Rodrigues P Nat Rev Gastroenterol Hepatol. 2023; 20(7):462-480.

PMID: 36755084 DOI: 10.1038/s41575-022-00739-y.


References
1.
Tiemersma E, Omer R, Bunschoten A, Vant Veer P, Kok F, Idris M . Role of genetic polymorphism of glutathione-S-transferase T1 and microsomal epoxide hydrolase in aflatoxin-associated hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev. 2001; 10(7):785-91. View

2.
Martignoni M, Groothuis G, de Kanter R . Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol. 2006; 2(6):875-94. DOI: 10.1517/17425255.2.6.875. View

3.
Yin L, Lynch D, Ilic Z, Sell S . Proliferation and differentiation of ductular progenitor cells and littoral cells during the regeneration of the rat liver to CCl4/2-AAF injury. Histol Histopathol. 2002; 17(1):65-81. DOI: 10.14670/HH-17.65. View

4.
Sell S, Dunsford H . Evidence for the stem cell origin of hepatocellular carcinoma and cholangiocarcinoma. Am J Pathol. 1989; 134(6):1347-63. PMC: 1879951. View

5.
Johnson N, Egner P, Baxter V, Sporn M, Wible R, Sutter T . Complete protection against aflatoxin B(1)-induced liver cancer with a triterpenoid: DNA adduct dosimetry, molecular signature, and genotoxicity threshold. Cancer Prev Res (Phila). 2014; 7(7):658-65. PMC: 4082474. DOI: 10.1158/1940-6207.CAPR-13-0430. View